On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will likely under no circumstances disappear and a vaccine will not quit it entirely. He also mentioned that ministers and experts should really quit ‘over-promising’ and be realistic about the prospects of a vaccine and the most likely timeline of one, unlikely prior to spring next year.
He then echoed his earlier warnings and these of his colleague Professor Chris Whitty that the COVID-19 fight will be a lengthy 1, and it will be with us for superior.
So, from pcr test chicago ought to we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single therapy that:
could quit the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in circumstances exactly where patients created secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug already confirmed as protected
was quick to make, scalable at the level expected to make a distinction in the pandemic and was cost powerful, then would not that be anything we need to all be finding excited about?
Surely although no such ‘silver bullet’ game changing therapy exists? Immediately after all, the only treatments we hear about for COVID are these which President Trump took, which were either really new, high priced and experimental or have a very narrow application to a certain aspect of the illness.
Effectively, you heard it right here initial – such a ‘silver bullet’ treatment does exist now. It’s named Nylexa®, from the compact UK biotech enterprise NovaBiotics Ltd. It is active components have been safely used in medicines that treat unrelated conditions for more than 30 years.
NovaBiotics discovered Nylexa’s possible advantages in COVID-19 following a decade of analysis in difficult to treat, drug-resistant infections, like the complex chest infections and inflammation associated with cystic fibrosis (CF) lung illness. In March they applied for a £1m grant from Innovate UK (representing the government) to start off clinical research. That grant was eventually awarded earlier this month, and the government are now taking into consideration no matter if or not to include Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so very good have we not heard about it ahead of? Why are the government and the press not shouting about this from the rooftops? Why is this not being demanded by clinicians desperate for productive treatments for their patients?
I’m afraid to say, it all boils down to funds. Small biotech firms find it hard to get interest as they never have the sources accessible to their bigger improved funded rivals. The names we read about often when it comes to ground breaking new treatment options are invariably significant multi-national pharmaceutical businesses with deep pockets and large budgets to promote their own certain wares. They make confident their drugs get the essential attention. NovaBiotics is a smaller private organization funded by a group of loyal and supportive shareholders so however don’t have the sources to compete for consideration with the big boys.
Which is why this situation is so frustrating. In mitigating the wellness consequences of contracting COVID-19, Nylexa® could increase public confidence of living with the virus for the longer term and potentially allow a higher degree of normality to return to the way in which we live, benefiting the economy straight in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. But obtaining individuals in positions of influence to take notice amongst all the others competing for their interest is quite difficult certainly.
It is reported that there are thousands of possible COVID-19 treatment options in clinical trials across the planet. I would challenge any person to show me 1 which has the exact same possible for constructive impact as Nylexa®, however this is not at the moment portion of any trial, in spite of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials quickly. The sooner it gets tested, the sooner it can be utilised to enable sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology enterprise focused on the style and improvement of very first-in-class therapies for challenging-to-treat, medically unmet infectiousdiseases brought on by bacteria and fungi and respiratory circumstances such as cystic fibrosis and COVID-19.
A leading innovator in the anti-infectives space, the Company’s robust technologies and organization model has been validated through thriving improvement, from idea to late stage clinical improvement, of its most sophisticated solution candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, high-value drug candidates like NP339 (Department of Wellness and Social Care funded programme) for life threatening, drug resistant invasive fungal disease and NP432 for multi- drug resistant bacterial infections.